UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 20, 2003
Callisto Pharmaceuticals, Inc.
------------------------------
(Exact name of registrant as specified in its charter)
Delaware 333-63474 65-110840
------------------------------------ --------- ---------
(State or other jurisdiction (Commission IRS Employer
of incorporation or organization) File Number) Identification No.)
420 Lexington Avenue, Suite 601
New York, New York 10170
------------------------
(Address of principal executive offices)
Registrant's telephone number, including area code: (212) 672-9190
--------------
Webtronics, Inc.
(Former name or former address, if changed since last report)
Item 5 Other Events
On March 10, 2003, as amended on April 4, 2003, we entered into a
merger agreement with Callisto Research Labs, LLC (formerly known as Callisto
Pharmaceuticals, Inc.), or Callisto Research and Synergy Pharmaceuticals, Inc.,
or Synergy, an unaffiliated company under which Callisto Research and Synergy
agreed to merge in a stock for stock transaction and each become our
subsidiaries. On April 30, 2003 the merger closed and we filed a Form 8-K Report
dated April 30, 2003 containing detailed information concerning the merger.
On May 20, 2003 we changed our name from Webtronics, Inc. to Callisto
Pharmaceuticals, Inc. and re-domesticated from Florida to Delaware by merging
into a wholly-owned subsidiary.
Our symbol on the over-the-counter Bulletin Board changed to CLSP
effective May 21, 2003.
We announced these changes in a press release dated May 28, 2003, which
is filed as an exhibit to this report.
We operate as a biopharmaceutical company focused on the development of
drugs to treat multiple myeloma, other cancers and osteolytic bone disease. Our
lead drug candidate, Atiprimod, is a small-molecule, orally available drug with
antiproliferative and antiangiogenic activity. Atiprimod successfully completed
Phase I clinical trials in rheumatoid arthritis patients and we plan to enter
Atiprimod in a safety and proof-of-principle clinical trial in multiple myeloma
patients. The drug is also being explored as an agent to treat osteolytic bone
disease. In addition, we have programs focused on the development of an analog
of the human intestinal hormone, uroguanylin, to treat colon cancer, and drugs
to protect against staphylococcal and streptococcal bioweapons, as a protection
against the devastating effects of toxic shock syndrome.
Item 7 Financial Statements, Pro Forma Financial Information and Exhibits.
(a) Financial Statements
None
(b) Pro Forma Financial Statements of Callisto Pharmaceuticals, Inc.
None
(c) Exhibits
Exhibit No. Description
----------- -----------
2.1 Agreement and Plan of Merger dated March 10, 2003*
2.2 Amendment to Agreement and Plan of Merger dated April 4, 2003**
4.1 Form of Callisto Stock Certificate
99.1 Certificate of Incorporation of Callisto Pharmaceuticals, Inc.
99.2 By-laws of Callisto Pharmaceuticals, Inc.
99.3 Certificate of Merger - Delaware
99.4 Articles of Merger - Florida
99.5 Press Release dated May 28, 2003.
*Incorporated by reference to Exhibit 2.1 of Form 8-K filed March 19, 2003.
**Incorporated by reference to Exhibit 2.2 of Form 8-K filed May 15, 2003.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereto duly authorized.
Dated: May 28, 2003
CALLISTO PHARMACEUTICALS, INC.
/s/ Christoph Bruening
By: ____________________________________
Christoph Bruening
President